title: Nitric oxide in gastroprotection by aluminium-containing antacids.
abstract: Pretreatment with aluminium-containing antacids at their original pH or after acidification is known to protect the gastric mucosa against the damaging action of strong irritants and this protection is accompanied by an increase in gastric blood flow (GBF) but the mechanisms underlying these effects have not been elucidated. We investigated the role of endogenous nitric oxide (NO) and prostaglandins (PS) in the prevention of ethanol-induced gastric damage and the alteration of GBF by Maalox and its active component Al(OH)3. Maalox and Al(OH)3 at their original and acidic pH induced dose-dependent gastroprotection accompanied by attenuation of the reduction in GBF caused by 100% ethanol; similar protective and hyperemic effects were recorded after treatment with nocloprost, a locally active PGE2 analog, and nitroglycerin, a donor of NO. Pretreatment with indomethacin that suppressed mucosal PGE2 by about 90%, failed to affect the protective influence of Maalox or Al(OH)3 at their original or acidic pH. On the contrary, pretreatment with NG-nitro-L-arginine (L-NNA), a potent selective inhibitor of NO synthase, reversed the gastroprotective and hyperemic effects of Maalox or Al(OH)3 at original and acidic pH and this reversal was significantly antagonized by L-arginine but not D-arginine. The gastroprotective and hyperemic effects of nocloprost were not influenced by the pretreatment with L-NNA. We conclude that aluminium-containing antacids activate the NO system, which may contribute to the gastroprotective activity of these drugs through an increase in mucosal microcirculation.
authors: Institute of Physiology, University Medical School, Krakow, Poland.
authors: S J
authors: SJ
authors: Konturek
authors: T
authors: T
authors: Brzozowski
authors: J
authors: J
authors: Majka
authors: A
authors: A
authors: Szlachcic
authors: C
authors: C
authors: Nauert
authors: B
authors: B
authors: Slomiany
mesh_terms: D000536:Aluminum Hydroxide / Q000494:pharmacology*; D000818:Animals; D000863:Antacids / Q000494:pharmacology*; D001120:Arginine / Q000031:analogs & derivatives / Q000494:pharmacology; D015232:Dinoprostone / Q000378:metabolism; D004338:Drug Combinations; D000431:Ethanol / Q000633:toxicity*; D005753:Gastric Mucosa / Q000098:blood supply / Q000187:drug effects*; D006863:Hydrogen-Ion Concentration; D008276:Magnesium Hydroxide / Q000494:pharmacology*; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism*; D019335:Nitroarginine; D005996:Nitroglycerin / Q000494:pharmacology; D011461:Prostaglandins F, Synthetic / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012039:Regional Blood Flow / Q000187:drug effects
chemical_list: D000863:Antacids; D004338:Drug Combinations; D011461:Prostaglandins F, Synthetic; D019335:Nitroarginine; D009569:Nitric Oxide; C013591:aluminum hydroxide, magnesium hydroxide, drug combination; D000431:Ethanol; D000536:Aluminum Hydroxide; C048895:nocloprost; D001120:Arginine; D005996:Nitroglycerin; D015232:Dinoprostone; D008276:Magnesium Hydroxide